ERBB2 and neoplasm: Some oncologists will discuss treatment with younger women deemed to present numerous risk factors, such as a high tumour grade, multifocality, and an ER/PR-negative status, but, generally, chemotherapy and anti-HER2 treatment would not be offered to women with T1aN0 HER2-positive disease.